Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NUS) 2Q26
Stonegate Capital Partners updated coverage of NU Skin Enterprises (NUS) after 2Q26 results. Revenue was $320.1M versus an estimate of $345.2M; adjusted EPS was $0.20, matching estimates. GAAP EPS was $(5.14) due to $78.9M goodwill impairment and $167.5M deferred-tax valuation allowance. FY26 revenue guidance was cut to $1.28B-$1.35B and adjusted EPS to $0.70-$0.90.
How this was made
The 30-second read
Why it matters
The actionable signal is the guidance reset: FY26 revenue lowered to $1.28B-$1.35B and adjusted EPS to $0.70-$0.90, alongside India moving to 1H27. These changes can drive estimate revisions and near-term positioning, even as core gross margin improves and Prysm iO adoption continues.
Market read
Guidance cut and India timing shift are likely to pressure near-term expectations, while improving core gross margin and Prysm iO rollout provide a counterbalance for 2027 execution.
What to watch
The article emphasizes GAAP distortions from goodwill impairment and deferred-tax valuation allowance; traders may focus more on adjusted operating margin trajectory and sales-force stabilization than on GAAP EPS.
Background
Stonegate Capital Partners updates coverage on NU Skin Enterprises, summarizing 2Q26 performance and management’s revised FY26 outlook, including Prysm iO rollout progress and India operational timing.
Ticker impact
Stonegate coverage cites NU Skin 2Q26 results and a FY26 revenue and adjusted EPS guidance cut, plus margin and India timing changes.
Near-term downside bias versus prior expectations, with volatility tied to whether Prysm iO adoption and sales-force productivity can offset the softer FY26 setup.
The article’s newest concrete facts are the FY26 guidance reset (revenue and adjusted EPS) and India shifting to 1H27, both of which typically pressure near-term estimates. It also notes core gross margin improvement and Prysm iO progress, which can limit downside but does not negate the guidance cut.
Market effects
Highlights ongoing investment in AI-enabled beauty/wellness platforms (Prysm iO) and the sensitivity of direct-sales productivity to training and operating-model changes.
India timing shift to 1H27 suggests delayed contribution from local sourcing, logistics, and affiliate-model refinements.
Reinforces that consumer wellness direct-sales growth and margins remain highly dependent on execution in key regions and technology-driven productivity tools.
Counterpoint
Core Nu Skin gross margin improved and Prysm iO metrics (devices placed and scans) are progressing, which could mean the guidance cut is largely timing-related rather than demand-related.
Key entities
- companyNU Skin Enterprises Inc.
Subject of the coverage update, with 2Q26 results and lowered FY26 revenue and adjusted EPS guidance.
- product_platformPrysm iO
AI-enabled device and platform described as a central growth initiative, with device placement and scan metrics cited.
- research_firmStonegate Capital Partners
Analyst coverage provider summarizing results and guidance changes.
